Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Ping-Yun Ou"'
Autor:
Lin Li, Chia-Lang Hsu, Liang-In Lin, Bin-Shyun Lee, Ping-Yun Ou, Ann-Lii Cheng, Chiun Hsu, Da-Liang Ou
Publikováno v:
Cancer Research. 83:376-376
As part of our previous studies on the anti-tumor mechanisms of sorafenib, one of the primary treatments for advanced hepatocellular carcinoma (HCC), we found that suppression of cyclin E1 in HCC cells correlates with sensitivity to sorafenib (Chiun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7973f45ac0f9f21f7c0c079118a62c9f
https://doi.org/10.1158/1538-7445.am2023-376
https://doi.org/10.1158/1538-7445.am2023-376
Autor:
Ching-Hung Hsieh, Cheng-Zhe Jian, Liang-In Lin, Guan-Sian Low, Ping-Yun Ou, Chiun Hsu, Da-Liang Ou
Publikováno v:
Cancers
Cancers, Vol 14, Iss 294, p 294 (2022)
Cancers, Vol 14, Iss 294, p 294 (2022)
Simple Summary Immunotherapy is currently the backbone of new drug treatments for many cancer patients. CXC chemokine ligand 13 (CXCL13) is an important factor involved in recruiting immune cells that express CXC chemokine receptor type 5 (CXCR5) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c06f4bcfc3b13ec0415a68d063b60b86
https://doi.org/10.3390/cancers14020294
https://doi.org/10.3390/cancers14020294